D. Boral Capital Cuts Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target to $2.00

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its target price cut by D. Boral Capital from $3.00 to $2.00 in a research report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also recently issued reports on LCTX. Maxim Group reduced their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, January 10th. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Friday, January 31st.

Lineage Cell Therapeutics Stock Up 6.9 %

Shares of NYSEAMERICAN:LCTX opened at $0.69 on Tuesday. The company has a market cap of $150.99 million, a PE ratio of -5.71 and a beta of 1.21. Lineage Cell Therapeutics has a one year low of $0.48 and a one year high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its position in Lineage Cell Therapeutics by 1,058.3% in the 4th quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company’s stock valued at $1,147,000 after acquiring an additional 2,085,972 shares in the last quarter. Defender Capital LLC. raised its stake in shares of Lineage Cell Therapeutics by 19.2% in the 4th quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock valued at $2,997,000 after purchasing an additional 961,150 shares during the period. Red Crane Wealth Management LLC bought a new stake in shares of Lineage Cell Therapeutics in the fourth quarter valued at about $171,000. JPMorgan Chase & Co. boosted its position in shares of Lineage Cell Therapeutics by 39.8% during the fourth quarter. JPMorgan Chase & Co. now owns 946,399 shares of the company’s stock worth $476,000 after buying an additional 269,237 shares during the period. Finally, Barclays PLC grew its holdings in shares of Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after buying an additional 159,924 shares in the last quarter. Institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.